The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Neil M. Iyengar
No relevant relationships to disclose
Patrick Glyn Morris
Honoraria - Nordic Group; Novartis
Sujata Patil
No relevant relationships to disclose
Carol Chen
No relevant relationships to disclose
Alyson Abbruzzi
No relevant relationships to disclose
Robert James Lehman
No relevant relationships to disclose
Richard Steingart
No relevant relationships to disclose
Kevin C. Oeffinger
No relevant relationships to disclose
Nancy U. Lin
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - Genentech; GlaxoSmithKline
Beverly Moy
No relevant relationships to disclose
Steven E. Come
No relevant relationships to disclose
Eric P. Winer
Consultant or Advisory Role - Genentech (U); Merrimack Pharmaceuticals (U); Novartis (U); Pfizer (U)
Research Funding - Genentech
Larry Norton
No relevant relationships to disclose
Clifford Hudis
Research Funding - Merck
Chau T. Dang
Consultant or Advisory Role - Genentech
Research Funding - Genentech; GlaxoSmithKline